Tag: Lung Cancer
Success for serplulimab plus chemotherapy in small cell lung cancer
Adagrasib safe and clinically active in non-small cell lung cancer
Long-term benefits of combined immunotherapy over chemotherapy in non-small cell lung cancer
Effect of KRAS mutations and PD-L1 expression on therapy response in non-small cell lung cancer
Neoadjuvant nivolumab plus chemotherapy improves surgical outcomes in NSCLC
Immune-related adverse events are associated with efficacy of atezolizumab in patients with advanced NSCLC
Sustained efficacy of nivolumab/ipilimumab plus 2 cycles of chemotherapy in NSCLC
Patritumab deruxtecan (HER3-DXd) in EGFR TKI-resistant NSCLC
Lung cancer screening: Most patients not eligible 1-2 years prior to diagnosis
Biomarkers: a novel tool to improve lung nodule classification
Distinct changes in lung microbiome precede clinical diagnosis of lung cancer
Social smoking: Do not underestimate the risks
Higher thrombotic risk in NSCLC patient with ALK rearrangement
Mixed data: AMG 510 in tumours with KRASG12C
Neoadjuvant nivolumab/ipilimumab shows promise in resectable NSCLC
Overcoming the challenges of immunotherapy in non–small cell lung cancer
Repotrectinib shows encouraging safety, efficacy for patients with ROS1+ NSCLC
Pembrolizumab monotherapy leads to 5-year survival in some patients with NSCLC
Novel RET inhibitor BLU-667 offers promise for RET+ advanced NSCLC
Lurbinectedin shows promise as second-line therapy for SCLC
Early results from TAK-788 in NSCLC with EGFR exon 20 insertions
Experiences from Germany
Post-discontinuation immunotherapy in PACIFIC
Molecular characteristics of SCLC
I-O monotherapy
Incidence and local treatment
Tumour, node, and metastasis (TNM) staging system
Combo I-O plus chemotherapy
Brain irradiation as treatment option
Other I-O combinations
Experiences from France
